{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:21:25Z","timestamp":1791328885991,"version":"4.3.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.coph.2016.02.005","type":"journal-article","created":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T19:32:38Z","timestamp":1456947158000},"page":"78-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Mineralocorticoid receptor antagonists\u2014pharmacodynamics and pharmacokinetic differences"],"prefix":"10.1016","volume":"27","author":[{"given":"Jun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morag J","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2016.02.005_bib0320","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0022-3565(25)25602-6","article-title":"Pharmacology of a new steroid that blocks salt activity of aldosterone and desoxycorticosterone","volume":"126","author":"Kagawa","year":"1959","journal-title":"J Pharmacol Exp Therap"},{"key":"10.1016\/j.coph.2016.02.005_bib0325","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","article-title":"The evolution of aldosterone antagonists","volume":"217","author":"Garthwaite","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.coph.2016.02.005_bib0330","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1093\/emboj\/17.12.3317","article-title":"Antagonism in the human mineralocorticoid receptor","volume":"17","author":"Fagart","year":"1998","journal-title":"Embo J"},{"key":"10.1016\/j.coph.2016.02.005_bib0335","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1042\/bj2820697","article-title":"Aldosterone antagonists destabilize the mineralocorticosteroid receptor","volume":"282","author":"Couette","year":"1992","journal-title":"Biochem J"},{"key":"10.1016\/j.coph.2016.02.005_bib0340","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.1973.03220280028007","article-title":"Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program","volume":"225","author":"Greenblatt","year":"1973","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2016.02.005_bib0345","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/0006-2952(74)90386-4","article-title":"Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors","volume":"23","author":"Funder","year":"1974","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.coph.2016.02.005_bib0350","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","article-title":"Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro","volume":"240","author":"de Gasparo","year":"1987","journal-title":"J Pharmacol Exp Therap"},{"key":"10.1016\/j.coph.2016.02.005_bib0355","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1440-1681.2004.04079.x","article-title":"Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor","volume":"31","author":"Rogerson","year":"2004","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.coph.2016.02.005_bib0360","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2174\/1389557054553811","article-title":"Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone","volume":"5","author":"Hu","year":"2005","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.coph.2016.02.005_sbref0365","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.coph.2016.02.005_bib0370","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1124\/dmd.31.11.1448","article-title":"Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans","volume":"31","author":"Cook","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.coph.2016.02.005_bib0375","first-page":"893","article-title":"Mineralocorticoid excess, dietary sodium, and myocardial fibrosis","volume":"120","author":"Brilla","year":"1992","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.coph.2016.02.005_bib0380","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3181\/00379727-104-25782","article-title":"Protection by a steroid-spirolactone against certain types of cardiac necroses","volume":"104","author":"Selye","year":"1960","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.coph.2016.02.005_bib0385","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1210\/en.2004-0005","article-title":"Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone\/salt-treated rats","volume":"145","author":"Young","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.coph.2016.02.005_bib0390","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1161\/01.CIR.0000039104.56479.42","article-title":"Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure","volume":"106","author":"Suzuki","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2016.02.005_bib0395","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.02.005_bib0400","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.02.005_bib0405","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2016.02.005_bib0410","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2016.02.005_bib0415","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the aldo-dhf randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2016.02.005_bib0420","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1210\/jc.2007-0393","article-title":"Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus","volume":"92","author":"Joffe","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2016.02.005_bib0425","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.coph.2012.12.007","article-title":"Mineralocorticoid receptor antagonists for therapy of coronary artery disease and related complications","volume":"13","author":"Zwadlo","year":"2013","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.coph.2016.02.005_sbref0430","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.coph.2016.02.005_sbref0435","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1172\/JCI61427","article-title":"Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy","volume":"122","author":"Zhao","year":"2012","journal-title":"J Clin Investig"},{"key":"10.1016\/j.coph.2016.02.005_bib0440","first-page":"310","article-title":"Oral eplerenone for the management of chronic central serous chorioretinopathy","volume":"8","author":"Singh","year":"2015","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.coph.2016.02.005_bib0445","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1096\/fj.15-276782","article-title":"Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target","volume":"29","author":"Chadwick","year":"2015","journal-title":"Faseb J"},{"key":"10.1016\/j.coph.2016.02.005_bib0450","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ Heart Failure"},{"key":"10.1016\/j.coph.2016.02.005_bib0455","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","article-title":"Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist","volume":"7","author":"Vardeny","year":"2014","journal-title":"Circ Heart Failure"},{"key":"10.1016\/j.coph.2016.02.005_sbref0460","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","article-title":"Nonsteroidal antagonists of the mineralocorticoid receptor","volume":"24","author":"Kolkhof","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.coph.2016.02.005_bib0465","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fphar.2013.00115","article-title":"PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy","volume":"4","author":"Orena","year":"2013","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2016.02.005_bib0470","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.114.221341","article-title":"DSR-71167, a novel mineralocorticoid receptor antagonist with carbonic anhydrase inhibitory activity, separates urinary sodium excretion and serum potassium elevation in rats","volume":"354","author":"Nariai","year":"2015","journal-title":"J Pharmacol Exp Therap"},{"key":"10.1016\/j.coph.2016.02.005_bib0475","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2016.02.005_sbref0480","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.coph.2016.02.005_bib0485","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.1021\/jm100506y","article-title":"Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists","volume":"53","author":"Arhancet","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.coph.2016.02.005_bib0490","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2010.03.018","article-title":"The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family","volume":"635","author":"Kosaka","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2016.02.005_bib0495","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.bbrc.2010.04.149","article-title":"Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity","volume":"396","author":"Matsui","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.coph.2016.02.005_bib0500","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.107.103580","article-title":"A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity","volume":"51","author":"Dietz","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.coph.2016.02.005_sbref0505","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2016.02.005_bib0510","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1124\/mol.51.2.285","article-title":"Cell-specific, promoter-dependent mineralocorticoid agonist activity of spironolactone","volume":"51","author":"Massaad","year":"1997","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.coph.2016.02.005_bib0515","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.coph.2016.02.005_sbref0520","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2016.02.005_sbref0525","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2016.02.005_bib0530","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1161\/01.HYP.35.5.1099","article-title":"Role of 11{beta}-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries","volume":"35","author":"Alzamora","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.coph.2016.02.005_bib0535","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1210\/en.2003-1137","article-title":"Rapid, nongenomic effects of aldosterone in the heart mediated by {epsilon} protein kinase C","volume":"145","author":"Mihailidou","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.coph.2016.02.005_bib0540","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1210\/en.2004-1130","article-title":"Eplerenone blocks nongenomic effects of aldosterone on the Na+\/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels","volume":"146","author":"Michea","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.coph.2016.02.005_bib0545","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1210\/ME.2014-1410","article-title":"Role of nongenomic signaling pathways activated by aldosterone during cardiac reperfusion injury","volume":"29","author":"Ashton","year":"2015","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.coph.2016.02.005_bib0550","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1210\/me.2004-0537","article-title":"The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms","volume":"19","author":"Hultman","year":"2005","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.coph.2016.02.005_bib0555","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2016.02.005_bib0560","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1210\/me.2010-0193","article-title":"Identification of ligand-selective peptide antagonists of the mineralocorticoid receptor using phage display","volume":"25","author":"Yang","year":"2011","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.coph.2016.02.005_sbref0565","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1210\/me.2014-1101","article-title":"Use of phage display to identify novel mineralocorticoid receptor-interacting proteins","volume":"28","author":"Yang","year":"2014","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.coph.2016.02.005_bib0570","doi-asserted-by":"crossref","first-page":"e23793","DOI":"10.1371\/journal.pone.0023793","article-title":"Importance of suitable reference gene selection for quantitative real-time PCR: special reference to mouse myocardial infarction studies","volume":"6","author":"Everaert","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coph.2016.02.005_sbref0575","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1517\/13543776.2014.854772","article-title":"Mineralocorticoid receptor modulators: a patent review (2007\u20132012)","volume":"24","author":"Collin","year":"2014","journal-title":"Expert Opin Therap Patents"},{"key":"10.1016\/j.coph.2016.02.005_bib0580","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1254\/jphs.10285FP","article-title":"SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity","volume":"115","author":"Nariai","year":"2011","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.coph.2016.02.005_bib0585","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1021\/jm500206r","article-title":"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-me thoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist","volume":"57","author":"Casimiro-Garcia","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.coph.2016.02.005_bib0590","doi-asserted-by":"crossref","first-page":"8616","DOI":"10.1021\/jm2011645","article-title":"Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists","volume":"54","author":"Hasui","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.coph.2016.02.005_bib0595","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1023\/A:1012168020545","article-title":"Interactions of aldosterone antagonist diuretics with human serum proteins","volume":"14","author":"Takamura","year":"1997","journal-title":"Pharma Res"},{"key":"10.1016\/j.coph.2016.02.005_bib0600","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0922-4106(93)90072-H","article-title":"Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands","volume":"247","author":"Rupprecht","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2016.02.005_bib0605","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1096\/fj.15-274266","article-title":"Cistrome of the aldosterone-activated mineralocorticoid receptor in human renal cells","volume":"29","author":"Le Billan","year":"2015","journal-title":"FASEB J"},{"key":"10.1016\/j.coph.2016.02.005_bib0610","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/000331977202301007","article-title":"Experience with the use of an aldosterone antagonist in selected hypertensive patients","volume":"23","author":"Kert","year":"1972","journal-title":"Angiology"},{"key":"10.1016\/j.coph.2016.02.005_bib0615","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cpt197925133","article-title":"Hydrochlorothiazide and spironolactone in hypertension","volume":"25","author":"Schrijver","year":"1979","journal-title":"Clin Pharmacol Therap"},{"key":"10.1016\/j.coph.2016.02.005_bib0620","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.coph.2016.02.005_bib0625","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/ndt\/gft281","article-title":"Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial","volume":"28","author":"Esteghamati","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.coph.2016.02.005_bib0630","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147148921630011X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147148921630011X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T12:10:45Z","timestamp":1748779845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147148921630011X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":63,"alternative-id":["S147148921630011X"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2016.02.005","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid receptor antagonists\u2014pharmacodynamics and pharmacokinetic differences","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2016.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}